They should have seen it coming. Maybe they did see it coming. But when you’re in the trenches—pulling 60-hour weeks, celebrating those FDA approvals at 11 PM via Zoom, watching your pipeline drug finally hit commercialization targets—you tell yourself this time will be different. It wasn’t. Last Tuesday, they got the calendar invite. You know…
The pharma industry today has many enthusiastic newcomers… and empty seats where experienced medical and commercial leaders once sat. At first glance, it appears to be a “transformation.” In reality, it’s an exodus — one fueled by cost-cutting, short-term thinking, and a dangerous misunderstanding of what expertise actually means. Pharma isn’t “evolving.” Pharma is pushing out…
The pharma industry stands at a crossroads. For decades, the blockbuster drug model—developing a single medication that generates billions in annual revenue—has been the cornerstone of Big Pharma’s success. But mounting pressures from multiple directions are forcing industry leaders to ask an uncomfortable question: Is this business model sustainable, or are we witnessing its slow…
The Video Advertising Bureau’s new report, “TV Means Business — Pharma,” reads like a love letter to television. It claims that pharma brands pouring money into TV are reaping massive rewards — skyrocketing search traffic, surging website visits, and billions in revenue growth. But behind the glossy charts and confident headlines lies a serious problem: the data…
The pharmaceutical industry has long been considered a recession-proof sector—a safe harbor where innovation never sleeps and talent is always in demand. But if you’re currently job hunting in pharma, you’ve likely discovered a harsh truth: even this traditionally stable industry isn’t immune to the brutal hiring landscape of 2025. The Great Pharma Slowdown What’s…
Biotech is a high-stakes business where hope often runs ahead of reality. Few stories illustrate this better than Geron, once a symbol of biotech’s boundless promise—and now a cautionary tale of a failed commercial strategy and the firing of people who dared to put business ahead of ratings on how they get along with others. 1….
The meteoric rise of GLP-1 drugs like Ozempic and Wegovy captured headlines, drove pharma stocks to record highs, and promised to revolutionize obesity treatment. Now that prescription growth is beginning to level out, we’re left asking an uncomfortable question: Why didn’t we see this coming? The warning signs were always there. We just chose not…
People often mistake criticism for cynicism. But my critique of pharma marketing doesn’t come from bitterness or boredom—it comes from love. I’ve spent my career in this industry, and I believe deeply in its potential to inform, empower, and improve lives. That’s precisely why I can’t stand by and watch it lose its way. Pharma…
The pharma industry has long grappled with a trust problem. Despite developing life-saving medications and groundbreaking treatments, pharma companies often feel distant and impersonal to the patients they serve. The solution isn’t just better science—it’s better empathy. Understanding the Empathy Gap Patients navigating chronic illness, rare diseases, or new diagnoses don’t just need medication. They…
The pharmaceutical industry is facing an unprecedented challenge: the U.S. Food and Drug Administration, long considered the gold standard of global drug regulation, is hemorrhaging talent at an alarming rate. With thousands of employees departing through layoffs, early retirements, and voluntary resignations, the ripple effects are already being felt across the entire drug development ecosystem….